Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C26H36N2O4 |
| Molecular Weight | 440.575 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(CCNCCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1OC
InChI
InChIKey=UPKQNCPKPOLASS-UHFFFAOYSA-N
InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A validated method for the determination of verapamil and norverapamil in human plasma. | 2001 Jun |
|
| An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. | 2002 |
|
| Effects of grapefruit juice and smoking on verapamil concentrations in steady state. | 2002 Apr |
|
| Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. | 2002 May 15 |
|
| Verapamil: new insight into the molecular mechanism of drug oxidation in the human heart. | 2002 Sep 13 |
|
| Verapamil drug metabolism studies by automated in-tube solid phase microextraction. | 2002 Sep 5 |
|
| Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. | 2003 Aug |
|
| Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. | 2003 Jul |
|
| Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS(n) and LC-NMR. | 2003 Jun |
|
| Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. | 2003 May |
|
| HPLC/MS findings in a fatality involving sustained-release verapamil. | 2003 Sep |
|
| St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. | 2004 Apr |
|
| The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. | 2004 Dec |
|
| Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. | 2004 Feb |
|
| Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. | 2004 Mar |
|
| Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry. | 2004 May 25 |
|
| Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. | 2005 Apr |
|
| Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. | 2005 Feb |
|
| Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. | 2005 May |
|
| Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. | 2005 Oct |
|
| Kinetic study of CYP3A4 activity on verapamil by capillary electrophoresis. | 2005 Sep 15 |
|
| Chiral capillary electrophoretic analysis of verapamil metabolism by cytochrome P450 3A4. | 2006 Jul 7 |
|
| Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. | 2007 Dec 21 |
|
| Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. | 2008 May |
|
| Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. | 2008 Sep |
|
| Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied? | 2009 Mar |
|
| Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. | 2009 Mar |
|
| Clinically important interaction between tedisamil and verapamil. | 2009 May |
|
| Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. | 2010 Apr |
|
| Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. | 2010 Dec 14 |
|
| Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism. | 2010 Feb |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
957Z3K3R56
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
Norverapamil
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
SUB33734
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
DTXSID80873799
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
100000127677
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
104972
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
67018-85-3
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY | |||
|
266-544-8
Created by
admin on Sat Dec 16 10:21:34 GMT 2023 , Edited by admin on Sat Dec 16 10:21:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
